By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Portola Pharmaceuticals, Inc. 

270 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-246-7000 Fax: 650-246-7376


Portola Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation. Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of Factor Xa in phase three clinical trials for extended duration prophylaxis, or preventive treatment of a form of thrombosis known as venous thromboembolism, in acute medically ill patients; Andexanet alfa, a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor; and Cerdulatinib, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases, enzymes that regulate important signaling pathways.

Key Statistics

Ownership: Public

Web Site: Portola
Employees: 130
Symbol: PTLA

Start Up

Company News
Bay Area's Portola (PTLA) Wrangles Andexanet Alfa Deal Worth $120 Million from Bristol-Myers Squibb (BMY), Pfizer (PFE) 2/1/2016 5:42:47 AM
Portola (PTLA) To Webcast Corporate Update On January 12, 2016 1/8/2016 7:56:23 AM
Portola (PTLA) Announces Andexanet Alfa And Cerdulatinib Data Presentations At The 2015 American Society of Hematology Annual Meeting And Exposition 12/7/2015 12:07:16 PM
Portola (PTLA) Announces Proposed Offering Of Common Stock 12/4/2015 9:23:08 AM
Portola (PTLA) To Host Analyst And Investor Day On November 19 11/12/2015 11:06:18 AM
The New England Journal of Medicine Publishes Results Of Portola (PTLA)’ Phase 3 ANNEXA Studies Of Andexanet Alfa 11/11/2015 11:14:15 AM
The New England Journal of Medicine Publishes Results Of Portola (PTLA)’ Phase III ANNEXA Studies Of Andexanet Alfa 11/11/2015 10:12:36 AM
Portola (PTLA) Reports Third Quarter 2015 Financial Results And Provides Corporate Update 11/10/2015 9:50:49 AM
Portola (PTLA) Announces Phase 3 ANNEXA-R Part 2 Study Results To Be Presented At American Heart Association Scientific Sessions 2015 11/6/2015 10:52:46 AM
Portola (PTLA) To Present At Credit Suisse 24th Annual Healthcare Conference 11/4/2015 2:27:20 PM